Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Issued (2021 - 2025)

Amylyx Pharmaceuticals has reported Shares Issued over the past 5 years, most recently at $376000.0 for Q4 2025.

  • Quarterly results put Shares Issued at $376000.0 for Q4 2025, up 154.05% from a year ago — trailing twelve months through Dec 2025 was $4.1 million (up 91.23% YoY), and the annual figure for FY2025 was $4.1 million, up 91.23%.
  • Shares Issued for Q4 2025 was $376000.0 at Amylyx Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Over the last five years, Shares Issued for AMLX hit a ceiling of $200.9 million in Q1 2022 and a floor of -$200.6 million in Q2 2022.
  • Median Shares Issued over the past 5 years was $361500.0 (2023), compared with a mean of $786750.0.
  • Peak annual rise in Shares Issued hit 647954.84% in 2022, while the deepest fall reached 6688400.0% in 2022.
  • Amylyx Pharmaceuticals' Shares Issued stood at $145000.0 in 2021, then plummeted by 137140.0% to -$198.7 million in 2022, then skyrocketed by 100.17% to $347000.0 in 2023, then plummeted by 57.35% to $148000.0 in 2024, then skyrocketed by 154.05% to $376000.0 in 2025.
  • The last three reported values for Shares Issued were $376000.0 (Q4 2025), $2.7 million (Q3 2025), and $72000.0 (Q2 2025) per Business Quant data.